Solaxa has filed a notice of an exempt offering of securities to raise $6,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Solaxa is raising up to $6,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Christian Walker played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Solaxa
We are a Public Benefit Corporation dedicated to restoring the lives of patients with nerve damage by developing proven neuro-regenerative therapeutics that are accessible & impactful. Solaxa is a clinical-ready biopharmaceutical company developing treatments for rare neurodegenerative disease and nerve injury. We are pursuing both novel and reformulated drugs to restore nerve function by targeting ion channels.
To learn more about Solaxa, visit http://www.solaxa.com/
Solaxa Linkedin Page: https://www.linkedin.com/company/solaxa/
Contact:
Christian Walker, Chief Executive Officer
240-515-5765
https://www.linkedin.com/in/biowalk/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.